A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer

BACKGROUND: Nivolumab monotherapy has demonstrated superior efficacy in advanced unresectable gastric cancer (GC), but its impact on resectable GC remains unknown. This phase I study aimed to evaluate safety, feasibility, and potential biomarkers of neoadjuvant nivolumab monotherapy in resectable GC...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasegawa, Hirotaka, Shitara, Kohei, Takiguchi, Shuji, Takiguchi, Noriaki, Ito, Seiji, Kochi, Mitsugu, Horinouchi, Hidehito, Kinoshita, Takahiro, Yoshikawa, Takaki, Muro, Kei, Nishikawa, Hiroyoshi, Suna, Hideaki, Kodera, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013329/
https://www.ncbi.nlm.nih.gov/pubmed/35254550
http://dx.doi.org/10.1007/s10120-022-01286-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013329/
https://www.ncbi.nlm.nih.gov/pubmed/35254550
http://dx.doi.org/10.1007/s10120-022-01286-w

Ejemplares similares